536 related articles for article (PubMed ID: 34409551)
1. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.
de Moura Leite L; Cesca MG; Tavares MC; Santana DM; Saldanha EF; Guimarães PT; Sá DDS; Simões MFE; Viana RL; Rocha FG; Loose SK; Silva SF; Pirolli R; Fogassa CAZ; Mattos BRS; Campos FAB; Sanches SM; de Lima VCC; Pondé NF
Breast Cancer Res Treat; 2021 Nov; 190(1):155-163. PubMed ID: 34409551
[TBL] [Abstract][Full Text] [Related]
2. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
Li JJ; Yu Y; Ge J
Breast Cancer; 2023 May; 30(3):364-378. PubMed ID: 36656510
[TBL] [Abstract][Full Text] [Related]
3. Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Alves FR; Gil L; Vasconcelos de Matos L; Baleiras A; Vasques C; Neves MT; Ferreira A; Fontes-Sousa M; Miranda H; Martins A
Cureus; 2022 Feb; 14(2):e22330. PubMed ID: 35371692
[TBL] [Abstract][Full Text] [Related]
4. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
5. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
6. Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis.
Li H; Plichta JK; Li K; Jin Y; Thomas SM; Ma F; Tang L; Wei Q; He YW; Chen Q; Guo Y; Liu Y; Zhang J; Luo S
Breast Cancer Res Treat; 2024 Feb; 204(1):89-105. PubMed ID: 38066250
[TBL] [Abstract][Full Text] [Related]
7. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
8. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
Cherifi F; Da Silva A; Johnson A; Blanc-Fournier C; Abramovici O; Broyelle A; Levy C; Allouache D; Hrab I; Segura C; Morel A; Villemin M; Boscher C; Dubot-Poitelon C; Rottier P; Lequesne J; Emile G
BMC Cancer; 2022 Oct; 22(1):1081. PubMed ID: 36266623
[TBL] [Abstract][Full Text] [Related]
9. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
10. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
11. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
Weiss A; Bashour SI; Hess K; Thompson AM; Ibrahim NK
Breast Cancer Res; 2018 Apr; 20(1):27. PubMed ID: 29661243
[TBL] [Abstract][Full Text] [Related]
12. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Denkert C; Seither F; Schneeweiss A; Link T; Blohmer JU; Just M; Wimberger P; Forberger A; Tesch H; Jackisch C; Schmatloch S; Reinisch M; Solomayer EF; Schmitt WD; Hanusch C; Fasching PA; Lübbe K; Solbach C; Huober J; Rhiem K; Marmé F; Reimer T; Schmidt M; Sinn BV; Janni W; Stickeler E; Michel L; Stötzer O; Hahnen E; Furlanetto J; Seiler S; Nekljudova V; Untch M; Loibl S
Lancet Oncol; 2021 Aug; 22(8):1151-1161. PubMed ID: 34252375
[TBL] [Abstract][Full Text] [Related]
14. Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer.
Yi X; Hu S; Ma M; Huang D; Zhang Y
Clin Transl Oncol; 2024 Apr; 26(4):880-890. PubMed ID: 37702827
[TBL] [Abstract][Full Text] [Related]
15. Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis.
Shao Y; Yu Y; Luo Z; Guan H; Zhu F; He Y; Chen Q; Liu C; Nie B; Liu H
Ann Surg Oncol; 2022 Dec; 29(13):8026-8034. PubMed ID: 35933542
[TBL] [Abstract][Full Text] [Related]
16. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
17. In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment.
Lien HC; Lo C; Lee YH; Lin PH; Wang MY; Kuo WH; Tsai LW; Lu YS; Hu HW; Li YC; Huang CS
Breast Cancer Res; 2024 Jun; 26(1):100. PubMed ID: 38867307
[TBL] [Abstract][Full Text] [Related]
18. Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Whitworth P; Stork-Sloots L; de Snoo FA; Richards P; Rotkis M; Beatty J; Mislowsky A; Pellicane JV; Nguyen B; Lee L; Nash C; Gittleman M; Akbari S; Beitsch PD
Ann Surg Oncol; 2014 Oct; 21(10):3261-7. PubMed ID: 25099655
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer.
Wang Y; Singh K; Dizon D; Graves T; Amin A; Yakirevich E
Breast Cancer Res Treat; 2021 Apr; 186(3):667-676. PubMed ID: 33598878
[TBL] [Abstract][Full Text] [Related]
20. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors.
Salim DK; Mutlu H; Eryilmaz MK; Musri FY; Tural D; Gunduz S; Coskun HS
Asian Pac J Cancer Prev; 2014; 15(21):9379-83. PubMed ID: 25422228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
